Skip to main content
Erschienen in:

07.07.2020 | Original Article

Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus

verfasst von: Dai Shimizu, Masahiko Koike, Mitsuro Kanda, Fuminori Sonohara, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Suguru Yamada, Yasuhiro Kodera

Erschienen in: Surgery Today | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated the efficacy of the long-term follow-up of patients who underwent radical esophagectomy for esophageal squamous cell carcinoma (ESCC) to screen for recurrence and new primary malignancies.

Methods

We retrospectively collected 448 ESCC patients who underwent radical esophagectomy. Esophagogastroduodenoscopy, computed tomography, a stool test and the assessment of the serum concentration of squamous cell carcinoma antigen and carcinoembryonic antigen were performed annually, even over 5 years after esophagectomy. The incidence of ESCC recurrence and new primary malignancies was investigated.

Results

We enrolled 222 patients who survived at least 5 years after esophagectomy. A total of 104 new primary malignancies occurred in 82 patients (36.9%) after esophagectomy. Twenty-one malignancies were in the head and neck region, 14 in the residual esophagus, 13 in the prostate and 11 in the gastric tube and lung. Patients who developed new primary malignancies after esophagectomy had a significantly higher Brinkman index than those without new malignancies. An endoscopic approach successfully treated 92.9% of carcinomas in the residual esophagus, 90.9% of cancers in the gastric tube and 42.9% of carcinomas in the head and neck region.

Conclusion

The incidence of new primary malignancies was higher than the age-standardized incidence. Long-term follow-up and systemic screening may increase the probability of an early diagnosis and subsequent low-invasive treatment.
Literatur
2.
Zurück zum Zitat Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol. 2017;115(5):564–79.PubMed Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol. 2017;115(5):564–79.PubMed
3.
Zurück zum Zitat Kanda M, Koike M, Shimizu D, Tanaka C, Kobayashi D, Hattori N, et al. optimized cutoff value of serum squamous cell carcinoma antigen concentration accurately predicts recurrence after curative resection of squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2019. Kanda M, Koike M, Shimizu D, Tanaka C, Kobayashi D, Hattori N, et al. optimized cutoff value of serum squamous cell carcinoma antigen concentration accurately predicts recurrence after curative resection of squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2019.
4.
Zurück zum Zitat Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–96.PubMed Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–96.PubMed
5.
Zurück zum Zitat Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, et al. Risk prediction of postoperative pneumonia after subtotal esophagectomy based on preoperative serum cholinesterase concentrations. Ann Surg Oncol. 2019;26(11):3718–26.PubMed Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, et al. Risk prediction of postoperative pneumonia after subtotal esophagectomy based on preoperative serum cholinesterase concentrations. Ann Surg Oncol. 2019;26(11):3718–26.PubMed
6.
Zurück zum Zitat Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013;43(6):608–15.PubMed Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013;43(6):608–15.PubMed
7.
Zurück zum Zitat Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.PubMedPubMedCentral Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.PubMedPubMedCentral
8.
Zurück zum Zitat Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.PubMed Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.PubMed
9.
Zurück zum Zitat Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389(10076):1323–35.PubMedPubMedCentral Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389(10076):1323–35.PubMedPubMedCentral
10.
Zurück zum Zitat Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, et al. Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surg. 2019;19(1):143.PubMedPubMedCentral Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, et al. Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis. BMC Surg. 2019;19(1):143.PubMedPubMedCentral
11.
Zurück zum Zitat Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014;45(3):325–33.PubMed Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014;45(3):325–33.PubMed
12.
Zurück zum Zitat Polinder S, Verschuur EM, Siersema PD, Kuipers EJ, Steyerberg EW. Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer. Eur J Cancer. 2009;45(12):2110–5.PubMed Polinder S, Verschuur EM, Siersema PD, Kuipers EJ, Steyerberg EW. Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer. Eur J Cancer. 2009;45(12):2110–5.PubMed
13.
Zurück zum Zitat Katada C, Yokoyama T, Yano T, Kaneko K, Oda I, Shimizu Y, et al. Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 2016;151(5):860–9.e7.PubMed Katada C, Yokoyama T, Yano T, Kaneko K, Oda I, Shimizu Y, et al. Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 2016;151(5):860–9.e7.PubMed
14.
Zurück zum Zitat Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.PubMed Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.PubMed
15.
Zurück zum Zitat Tian D, Feng Z, Hanley NM, Setzer RW, Mumford JL, DeMarini DM. Multifocal accumulation of p53 protein in esophageal carcinoma: evidence for field cancerization. Int J Cancer. 1998;78(5):568–75.PubMed Tian D, Feng Z, Hanley NM, Setzer RW, Mumford JL, DeMarini DM. Multifocal accumulation of p53 protein in esophageal carcinoma: evidence for field cancerization. Int J Cancer. 1998;78(5):568–75.PubMed
16.
Zurück zum Zitat Fitzpatrick PJ, Tepperman BS, deBoer G. Multiple primary squamous cell carcinomas in the upper digestive tract. Int J Radiat Oncol Biol Phys. 1984;10(12):2273–9.PubMed Fitzpatrick PJ, Tepperman BS, deBoer G. Multiple primary squamous cell carcinomas in the upper digestive tract. Int J Radiat Oncol Biol Phys. 1984;10(12):2273–9.PubMed
17.
Zurück zum Zitat Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, et al. Association of oral microbiome with risk for incident head and neck squamous cell cancer. JAMA Oncol. 2018;4(3):358–65.PubMedPubMedCentral Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, et al. Association of oral microbiome with risk for incident head and neck squamous cell cancer. JAMA Oncol. 2018;4(3):358–65.PubMedPubMedCentral
18.
Zurück zum Zitat Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574–81.PubMed Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574–81.PubMed
19.
Zurück zum Zitat Hashimoto K, Shimizu D, Hirabayashi S, Ueda S, Miyabe S, Oh-Iwa I, et al. Changes in oral microbial profiles associated with oral squamous cell carcinoma vs leukoplakia. J Investig Clin Dent. 2019:e12445. Hashimoto K, Shimizu D, Hirabayashi S, Ueda S, Miyabe S, Oh-Iwa I, et al. Changes in oral microbial profiles associated with oral squamous cell carcinoma vs leukoplakia. J Investig Clin Dent. 2019:e12445.
20.
Zurück zum Zitat Chen D, Fan N, Mo J, Wang W, Wang R, Chen Y, et al. Multiple primary malignancies for squamous cell carcinoma and adenocarcinoma of the esophagus. J Thorac Dis. 2019;11(8):3292–301.PubMedPubMedCentral Chen D, Fan N, Mo J, Wang W, Wang R, Chen Y, et al. Multiple primary malignancies for squamous cell carcinoma and adenocarcinoma of the esophagus. J Thorac Dis. 2019;11(8):3292–301.PubMedPubMedCentral
21.
Zurück zum Zitat Sato Y, Motoyama S, Maruyama K, Okuyama M, Ogawa J. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201(2):188–93.PubMed Sato Y, Motoyama S, Maruyama K, Okuyama M, Ogawa J. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201(2):188–93.PubMed
22.
Zurück zum Zitat Natsugoe S, Matsumoto M, Okumura H, Ishigami S, Uenosono Y, Owaki T, et al. Multiple primary carcinomas with esophageal squamous cell cancer: clinicopathologic outcome. World J Surg. 2005;29(1):46–9.PubMed Natsugoe S, Matsumoto M, Okumura H, Ishigami S, Uenosono Y, Owaki T, et al. Multiple primary carcinomas with esophageal squamous cell cancer: clinicopathologic outcome. World J Surg. 2005;29(1):46–9.PubMed
23.
Zurück zum Zitat Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
24.
Zurück zum Zitat Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.PubMed Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.PubMed
25.
Zurück zum Zitat Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16(1):1–24.PubMed Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16(1):1–24.PubMed
26.
Zurück zum Zitat Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16(1):25–43.PubMed Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16(1):25–43.PubMed
27.
Zurück zum Zitat Chuang SC, Hashibe M, Scelo G, Brewster DH, Pukkala E, Friis S, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1543–9.PubMed Chuang SC, Hashibe M, Scelo G, Brewster DH, Pukkala E, Friis S, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1543–9.PubMed
28.
Zurück zum Zitat Natsugoe S, Uchino Y, Kijima F, Shimada M, Shirao K, Kusano C, et al. Synchronous and metachronous carcinomas of the esophagus and head and neck. Dis Esophagus. 1997;10(2):134–8.PubMed Natsugoe S, Uchino Y, Kijima F, Shimada M, Shirao K, Kusano C, et al. Synchronous and metachronous carcinomas of the esophagus and head and neck. Dis Esophagus. 1997;10(2):134–8.PubMed
29.
Zurück zum Zitat Kato M, Ishihara R, Hamada K, Tonai Y, Yamasaki Y, Matsuura N, et al. Endoscopic surveillance of head and neck cancer in patients with esophageal squamous cell carcinoma. Endosc Int Open. 2016;4(7):E752–E755755.PubMedPubMedCentral Kato M, Ishihara R, Hamada K, Tonai Y, Yamasaki Y, Matsuura N, et al. Endoscopic surveillance of head and neck cancer in patients with esophageal squamous cell carcinoma. Endosc Int Open. 2016;4(7):E752–E755755.PubMedPubMedCentral
30.
Zurück zum Zitat Katada C, Muto M, Tanabe S, Higuchi K, Sasaki T, Azuma M, et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection for esophageal squamous cell carcinoma. Dig Endosc. 2013;25(Suppl 1):39–433.PubMed Katada C, Muto M, Tanabe S, Higuchi K, Sasaki T, Azuma M, et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection for esophageal squamous cell carcinoma. Dig Endosc. 2013;25(Suppl 1):39–433.PubMed
Metadaten
Titel
Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus
verfasst von
Dai Shimizu
Masahiko Koike
Mitsuro Kanda
Fuminori Sonohara
Norifumi Hattori
Masamichi Hayashi
Chie Tanaka
Suguru Yamada
Yasuhiro Kodera
Publikationsdatum
07.07.2020
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 1/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02072-w

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.